Heidelberg Pharma Ag Stock Debt To Equity
HPHA Stock | EUR 2.41 0.04 1.63% |
Heidelberg Pharma AG fundamentals help investors to digest information that contributes to Heidelberg Pharma's financial success or failures. It also enables traders to predict the movement of Heidelberg Stock. The fundamental analysis module provides a way to measure Heidelberg Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Heidelberg Pharma stock.
Heidelberg |
Heidelberg Pharma AG Company Debt To Equity Analysis
Heidelberg Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition |
According to the company disclosure, Heidelberg Pharma AG has a Debt To Equity of 0.0%. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Debt To Equity (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Heidelberg Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Heidelberg Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Heidelberg Pharma could also be used in its relative valuation, which is a method of valuing Heidelberg Pharma by comparing valuation metrics of similar companies.Heidelberg Pharma is currently under evaluation in debt to equity category among its peers.
Heidelberg Fundamentals
Current Valuation | 194.72 M | |||
Price To Book | 24.79 X | |||
Price To Sales | 12.52 X | |||
Revenue | 1.75 M | |||
EBITDA | (24.84 M) | |||
Net Income | (26.14 M) | |||
Cash Flow From Operations | (26.61 M) | |||
Market Capitalization | 173.26 M | |||
Total Asset | 21.73 M | |||
Z Score | -3.3 | |||
Net Asset | 21.73 M |
About Heidelberg Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Heidelberg Pharma AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heidelberg Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heidelberg Pharma AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Heidelberg Stock
Heidelberg Pharma financial ratios help investors to determine whether Heidelberg Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Heidelberg with respect to the benefits of owning Heidelberg Pharma security.